Whitepaper
28 May 2025

Interview with Marga Viñes

PDF 802 kB

Grifols has emphasised its commitment to expanding its parenteral CDMO services, predominantly in the small molecule injectable field. What strategies is the company adopting to reinforce its position in this market? And how does this align with the growing demand for small molecule injectable therapeutics?

Content provided by our supplier

Grifols International, S.A.

  • ES
  • 2015
    On CPHI since
  • 4
    Certificates
  • 5000+
    Employees
Company types
CMO/CDMO
Contract Service
Primary activities
Contract Manufacturer
Custom Manufacturing/Custom Synthesis

Other Content from Grifols International, S.A. (15)